Glucagon-like peptide-1 (GLP-1) is an incretin composed of 30 amino acids, primarily secreted by L-cells in the gut. It acts on the GLP-1 receptor (GLP-1R) and stimulates insulin secretion while inhibiting glucagon secretion in a glucose-concentration-dependent manner. It also slows gastric emptying and gastrointestinal secretion and reduces food intake, thereby achieving blood sugar reduction and weight control [James G. Boyle et al., (2018) Clin Sci (Lond)].
GLP-1 receptor agonists, or analogs, mimic these beneficial actions in the treatment of type 2 diabetes, enhancing glycemic control and often supporting weight loss.
Due to its beneficial effects on glucose control and potential for weight loss, GLP-1 and its analogs have become a focus for the development of therapies for type 2 diabetes and obesity.
GLP-1 receptor agonists, which are synthetic versions of
the hormone, mimic the action
of natural GLP-1 and have been approved for the treatment of type 2 diabetes. These medications not only help to
improve glycemic control but also have been shown to have cardiovascular benefits in some patients.
Research continues to explore the broader therapeutic potential of GLP-1, including its effects on the
cardiovascular system, brain function, and its potential role in the treatment of conditions beyond type 2
diabetes, such as Parkinson's disease and Alzheimer's disease. The understanding of GLP-1 and its physiological
functions has significantly advanced our approach to managing conditions related to glucose metabolism and
obesity.
In the advancement of GLP-1 therapies, researchers employ fatty acid modification and Fc fusion protein techniques to enhance the effectiveness of GLP-1 receptor agonists. Recognizing the limitations of natural GLP-1's brief half-life, GenScript specializes in providing high-quality peptides that are essential for these sophisticated modifications.
To date, more than a dozen GLP-1 drugs have been launched globally. To better accelerate your GLP-1 new drug research and development, GenScript is now offering GLP-1 Receptor Agonist Services.
Read More about GenScript GLP-1 capability in the GenScript successful case section.
Need help from an expert?
One-Stop Service
From early drug screening, process development to cGMP production
Diversified Solutions
Robust modification techniques including advanced conjugation services with small-molecule drugs
Regulatory Compliance CMC Service
Streamlining GLP-1 analogs development and registration with comprehensive CMC services
From Drug Discovery to Support for Clinical Trials
| 1 | Drug Screening |
|
| 2 | CMC |
|
| 3 | Regulatory Support |
|
| 4 | Clinical & Commercialization |
|
Detection of GLP-1 RA peptide purity
by HPLC confirms high purity
Molecular weight of the GLP-1 RA peptide has been
accurately confirmed through mass spectrometry
detection
The purity of the GLP-1 RA peptide is consistent across
multiple synthesis batches
The solubility of the GLP-1 RA peptide remains consistent
across multiple synthesis batches
GenScript successfully delivered 30 g of GLP-1 RA peptide (95% purity) within 45 days
GenScript offers specialized expertise in peptide synthesis, with the capacity to support the development of cutting-edge hypoglycemic drugs targeting multiple receptors such as GLP-1 RA peptide including GLP-1 activating peptide of novel drug AMG133.
AMG133 represents a breakthrough conjugate treatment for type 2 diabetes, created to enhance patient convenience with a once-monthly dosing regimen. This innovative treatment synergistically combines a fully human monoclonal antibody, aimed at the GIP receptor (GIPR) — a target for blood sugar control — with a GLP-1 agonist peptide analog, which is a molecule designed to stimulate insulin release [Véniant, M.M. et al. Nat Metab (2024)].
Adapted from Véniant, M.M. et al. Nat Metab (2024) with modification.
At GenScript, we have the capabilities to synthesize complex peptides and linkers, which are crucial components in groundbreaking drugs like AMG133. Our advanced solutions are contributing to a revolutionary approach in the development of hypoglycemic drugs, particularly in the management of diabetes and support in weight loss.
